Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78821 | 1.00 | CYP2C9 (0.68) | CYP2C9CYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL29567211 | 1.00 | CYP2C9 (0.68) | CYP2C9CYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL29570568 | 1.00 | CYP2C9 (0.68) | CYP2C9CYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL29402853 | 1.00 | CYP2C9 (0.68) | CYP2C9CYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL38819 | 1.00 | CYP2C9 (0.68) | CYP2C9CYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL6852463 | 0.88 | CYP1A2 (0.55) | CYP2C9CYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL14410468 | 0.88 | CYP1A2 (0.55) | CYP2C9CYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL13651922 | 0.87 | CYP1A2 (0.66) | CYP2C9CYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL17983178 | 0.86 | CYP1A2 (0.53) | CYP2C9CYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL31258922 | 0.85 | CYP1A2 (0.84) | CYP2C9CYP1A2CYP2C19ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104961646-B | Mosapride active metabolites, preparation method and uses thereof | 沈阳药科大学 | 2017-02-22 | — | — | CN | claimed |
| EP-1377557-B1 | METHODS OF SYNTHESIZING HETEROATOM-BEARING LIGANDS AND INTERMEDIATE USED THEREFOR | BRACCO INT BV (NL) | 2006-04-05 | — | — | EP | claimed |
| US-6919379-B2 | Compounds useful in reflux disease | ASTRAZENECA AB (SE) | 2005-07-19 | — | — | US | claimed |
| US-20040152775-A1 | Compounds useful in reflux disease | ASTRAZENECA AB (SE) | 2004-08-05 | — | — | US | claimed |
| EP-3135669-B1 | OXAZOLIDINE-BASED COMPOUND AND SELECTIVE ANDROGEN RECEPTOR AGONIST COMPRISING SAME | DONG A ST CO LTD (KR) | 2024-08-28 | — | — | EP | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11248001-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2022-02-15 | — | — | US | disclosed |
| CN-110885325-B | Preparation method of (S) -glycidol phthalimide | 新发药业有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-11028101-B2 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD (AU) | 2021-06-08 | — | — | US | disclosed |
| WO-2003068743-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003055478-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-10 | — | — | WO | disclosed |
| US-6586474-B2 | Antiinflammatory agents | PHARMACIA CORPORATION | 2003-07-01 | — | — | US | disclosed |
| WO-2003018556-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
| WO-2002100823-A1 | NEW COMPOUNDS USEFUL IN REFLUX DISEASE | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | disclosed |
| US-20020111493-A1 | Amidino compounds useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-08-15 | — | — | US | disclosed |
| US-6403830-B2 | A S-(2-(1-IMINOETHYL)AMINO)ETHYL)-2-METHYL-L-CYSTEINE AND SALTS | PHARMACIA CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020019563-A1 | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248001-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | CYP2C9 1631/4885CYP1A2 2718/4885CYP2C19 1752/4885 |
| US-20040152775-A1 | Compounds useful in reflux disease | HRH2, HRH1, HRH4 | CYP2C9 341/4885CYP1A2 451/4885CYP2C19 391/4885 |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CYP2C9 4543/4885CYP1A2 4575/4885CYP2C19 4432/4885 |
| US-11028101-B2 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies | HBB, HBZ, HBG2 | CYP2C9 1305/4885CYP1A2 393/4885CYP2C19 1519/4885 |
| US-20020111493-A1 | Amidino compounds useful as nitric oxide synthase inhibitors | NOS2, NOS1, NOS3 | CYP2C9 295/4885CYP1A2 143/4885CYP2C19 164/4885 |
| US-20020019563-A1 | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors | NOS2, NOS1, NOS3 | CYP2C9 631/4885CYP1A2 772/4885CYP2C19 700/4885 |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | CYP2C9 2216/4885CYP1A2 3522/4885CYP2C19 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.